English title: Complete remission study Subtitle: Discontinuation of Mepolizumab or Dupilumab after at least 12 months without symptoms in patients with severe Chronic rhinosinusitis with polyps – a National Danish RCT study.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519628-25-00

Enrollment

Registered

2025-02-09

Start date

2025-04-03

Completion date

Unknown

Last updated

2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rrhinosinusitis with nasal polyps

Brief summary

What percentage of patients can stop the biologic treatment and still be in complete remission

Detailed description

Is there any differences in what drug the patients have been treated with

Interventions

DRUGDupixent 300 mg solution for injection in pre-filled syringe

DRUGNucala 100 mg powder for solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
What percentage of patients can stop the biologic treatment and still be in complete remission	—

Secondary

Measure	Time frame
Is there any differences in what drug the patients have been treated with	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026